Study to Detect Oral Administration of Budesonide in Women.

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

July 1, 2018

Study Completion Date

September 10, 2018

Conditions
Healthy
Interventions
DRUG

Budesonide

Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.

Trial Locations (1)

08003

IMIM, Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT03537326 - Study to Detect Oral Administration of Budesonide in Women. | Biotech Hunter | Biotech Hunter